NVision

NVision Imaging Technologies GmbH is a quantum technology company based in Ulm, Germany, founded in 2015. The company is focused on revolutionizing medical MRI imaging by leveraging quantum physics to develop advanced hyperpolarization technologies. These innovations allow MRI systems to non-invasively and routinely interrogate metabolic processes at the molecular level, which is particularly valuable for early assessment and monitoring of treatment response in cancer and other serious diseases.

NVision has developed a hyperpolarization platform based on parahydrogen, a long-lived quantum state of hydrogen, which enhances existing MRI capabilities to provide detailed metabolic insights that conventional imaging techniques cannot achieve. This technology enables virtually any MRI scanner to perform metabolic and molecular imaging suitable for routine clinical practice, broadening access to optimized, personalized treatment strategies.

The company’s core product, POLARIS, is a hyperpolarization device designed to be fast, robust, and user-friendly, comprising a polarizer, consumables, and customized service options. POLARIS supports both preclinical and clinical research applications, with initial shipments scheduled from early 2024. NVision’s technology aims to improve early diagnosis and precision medicine, particularly in oncology, by providing deeper insights into cancer therapy efficacy.

Supported by a diverse international team of senior engineers, physicists, and materials scientists, NVision has attracted Tier 1 investors from Silicon Valley, Europe, and Israel. The company has successfully raised substantial funding, including a Series A – II round totaling approximately $93.85 million, to advance its quantum-based imaging solutions. NVision holds multiple patents related to magnetic resonance imaging, nuclear magnetic resonance, and quantum computing.

Through its pioneering work, NVision is expanding the capabilities of MRI technology beyond anatomical imaging to metabolic and molecular imaging, fundamentally changing the role of MRI in clinical diagnostics and treatment monitoring. Its mission is to save lives by enabling earlier and more accurate detection of disease and more effective treatment planning.